Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Levodopa with ODM-104 vs Stalevo in Healthy Volunteers
NCT02554734Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of neluxicapone in Parkinson's disease (PD) (3 arms), sponsored by Orion Corporation. Primary endpoints: Levodopa Peak Plasma Concentration at Day 7 and Fluctuation of Levodopa Cmax/Cmin at Day 7. Started Aug 2015; status: completed.
02
Drugs
neluxicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02554734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02554734.